{"id":6025,"date":"2019-03-15T19:49:39","date_gmt":"2019-03-15T19:49:39","guid":{"rendered":"https:\/\/splmed.com\/?p=6025"},"modified":"2023-02-10T19:50:34","modified_gmt":"2023-02-10T19:50:34","slug":"spl-medical-receives-approval-for-clinical-trial-with-contrast-agent-ferrotran-in-10-top-radiology-centers","status":"publish","type":"post","link":"https:\/\/splmed.com\/english\/spl-medical-receives-approval-for-clinical-trial-with-contrast-agent-ferrotran-in-10-top-radiology-centers\/","title":{"rendered":"SPL Medical receives approval for Clinical Trial with contrast agent Ferrotran\u00ae in 10 top radiology centers."},"content":{"rendered":"<p><span class=\"s1\">SPL Medical BV has received approval of the German regulatory body for pharmaceutical products BfArM, to the start of a multicenter clinical trial of Ferrotran<\/span><span class=\"s2\"><sup>\u00ae<\/sup><\/span><span class=\"s1\">. This is a novel contrast agent (based on Ferumoxtran-10) for use in MRI (magnetic resonance imaging), developed for the (early) detection of lymph node metastases of prostate cancer. Ferrotran<\/span><span class=\"s2\"><sup>\u00ae<\/sup><\/span><span class=\"s1\">\u00a0is the only contrast agent that can detect lymph node metastases as small as 2 mm. Standard MRI or CT are normally not able to detect nodes smaller than 7-8 mm.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>SPL Medical BV has received approval of the German regulatory body for pharmaceutical products BfArM, to the start of a multicenter clinical trial of Ferrotran\u00ae. This is a novel contrast agent (based on Ferumoxtran-10) for use in MRI (magnetic resonance imaging), developed for the (early) detection of lymph node metastases of prostate cancer. Ferrotran\u00ae is the only contrast agent that can detect lymph node metastases as small as 2 mm. Standard MRI or CT are normally not able to detect nodes smaller than 7-8 mm.<\/p>","protected":false},"author":1,"featured_media":5922,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,22],"tags":[],"class_list":["post-6025","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-press-release"],"_links":{"self":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts\/6025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/comments?post=6025"}],"version-history":[{"count":1,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts\/6025\/revisions"}],"predecessor-version":[{"id":6026,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/posts\/6025\/revisions\/6026"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/media\/5922"}],"wp:attachment":[{"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/media?parent=6025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/categories?post=6025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/splmed.com\/english\/wp-json\/wp\/v2\/tags?post=6025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}